Cystatin C, E-Selectin, and Pulmonary Function as Markers of Renal Dysfunction in Chronic Obstructive Pulmonary Disease with Stable Ischemic Heart Disease

Abstract

Background: Chronic obstructive pulmonary disease (COPD) frequently coexists with ischemic heart disease (IHD), and this combination may amplify systemic inflammation, endothelial injury, and renal dysfunction. Sensitive markers capable of detecting early renal involvement in this multimorbid phenotype remain incompletely characterized.

Objective: To evaluate cystatin C, cystatin C-based estimated glomerular filtration rate (eGFR), E-selectin, and forced expiratory volume in 1 second (FEV₁) as markers of renal dysfunction in patients with COPD with stable IHD, and to examine their relationships with inflammatory and cardiac biomarkers.

Methods: This comparative observational study included 135 patients with GOLD II-IV COPD: 90 with stable IHD and 45 without IHD. Within each GOLD stage, 30 patients had COPD plus IHD and 15 had COPD alone. Spirometry, serum cystatin C, creatinine, E-selectin, tumor necrosis factor-alpha (TNF-α), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were assessed. eGFR was calculated from cystatin C. Pearson correlation and receiver operating characteristic (ROC) analyses were performed.

Results: Cystatin C increased progressively from GOLD II to IV and was higher in COPD plus IHD than COPD alone at each stage (1.39±0.02 vs 1.20±0.03 mg/L; 1.72±0.04 vs 1.54±0.04 mg/L; and 2.00±0.04 vs 1.90±0.03 mg/L, respectively; P<0.01 for each comparison). Corresponding eGFR values were lower in the comorbid group at GOLD II (70.1±1.5 vs 81.8±1.7 mL/min/1.73 m²; P<0.001) and GOLD III (61.4±1.2 vs 67.1±1.8; P<0.05), while both groups showed marked filtration impairment at GOLD IV (44.6±1.2 vs 46.6±1.4; P>0.05). E-selectin, TNF-α, and NT-proBNP were also higher in COPD plus IHD. FEV₁ was inversely correlated with NT-proBNP in the comorbid group, with stronger associations as COPD severity increased (r=-0.524, -0.578, and -0.724 for GOLD II, III, and IV, respectively). For identifying renal dysfunction, ROC AUCs were 0.86 (95% CI 0.79-0.92) for cystatin C, 0.78 (0.70-0.85) for E-selectin, and 0.71 (0.63-0.79) for FEV₁.

Conclusion: Renal filtration impairment in COPD worsened in parallel with airflow limitation and was accentuated by coexisting stable IHD, particularly at moderate and severe stages. Cystatin C showed the strongest discriminatory performance, while E-selectin and FEV₁ provided complementary information reflecting endothelial and pulmonary contributions to the pulmonary-cardiac-renal continuum.

Keywords:

Chronic obstructive pulmonary disease, Ischemic heart disease, Cystatin C, Estimated glomerular filtration rate, E-selectin, NT-proBNP, Renal dysfunction, Cardiorenal interaction

References

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. GOLD; 2026.

Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-349. doi:10.2147/COPD.S6400.

Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956-962. doi:10.1136/thx.2009.128082.

Yangui F, Touil A, Antit S, Zakhama L, Charfi MR. COPD prevalence in smokers with stable ischemic heart disease: a cross-sectional study in Tunisia. Respir Med. 2021;179:106335. doi:10.1016/j.rmed.2021.106335.

Liu Z, Ma Z, Ding C. Association between COPD and CKD: a systematic review and meta-analysis. Front Public Health. 2024;12:1494291. doi:10.3389/fpubh.2024.1494291.

Gaddam S, Gunukula SK, Lohr JW, Arora P. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2016;16(1):158. doi:10.1186/s12890-016-0315-0.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018.

Chai L, Feng W, Zhai C, Shi W, Wang J, Yan X, et al. The association between cystatin C and COPD: a meta-analysis and systematic review. BMC Pulm Med. 2020;20(1):182. doi:10.1186/s12890-020-01208-5.

Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J. Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost. 2001;7(3):205-208. doi:10.1177/107602960100700304.

Labaki WW, Xia M, Murray S, Curtis JL, Barr RG, Bhatt SP, et al. NT-proBNP in stable COPD and future exacerbation risk: analysis of the SPIROMICS cohort. Respir Med. 2018;140:87-93. doi:10.1016/j.rmed.2018.06.005.

Su X, Lei T, Yu H, Zhang L, Feng Z, Shuai T, et al. NT-proBNP in different patient groups of COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:811-825. doi:10.2147/COPD.S396663.

Silvestre OM, Nadruz W Jr, Querejeta Roca G, Claggett B, Solomon SD, Mirabelli MC, et al. Declining lung function and cardiovascular risk: the ARIC Study. J Am Coll Cardiol. 2018;72(10):1109-1122. doi:10.1016/j.jacc.2018.06.049.